Commentary: The pharmacological antioxidant amifostine - Implications of recent research for integrative cancer care

Integrative Cancer Therapies

Volumn 4, Issue 4, 2005, Pages 329-351

  Block, Keith I ^a,b,c   Gyllenhaal, Charlotte ^a,b  

^a Block Center for Integrative Cancer Care   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Amifostine; Antioxidant; Chemoradiation; Chemotherapy; Review

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; BUSULFAN; CAROTENOID; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; PACLITAXEL; SEROTONIN ANTAGONIST; VINBLASTINE; VITAMIN;

ACUTE LEUKEMIA; ALLERGY; ANAPHYLAXIS; ANTIOXIDANT ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROTECTION; CLINICAL TRIAL; DIARRHEA; ESOPHAGITIS; GYNECOLOGIC CANCER; HUMAN; HYPOCALCEMIA; HYPOTENSION; LUNG NON SMALL CELL CANCER; MELANOMA; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; OXIDATIVE STRESS; PHYTOCHEMISTRY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; VOMITING;

AMIFOSTINE; ANTIOXIDANTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG TOXICITY; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PRACTICE GUIDELINES;

EID: 28144453864     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735405282842     Document Type: Review

References (69)

1. Block KI. Antioxidants and cancer therapy: furthering the debate. Integr Cancer Ther. 2004;3:342-348.
2. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse events of head and neck cancer in head and neck cancer patients. J Clin Oncol. 2005;23:5805-5813.
3. Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther. 2004;3:310-322.
4. Pathak AK, Bhutani M, Guleria R, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005;24:16-21.
5. Koukourakis MI. Amifostine: is there evidence of tumor protection? Semin Oncol. 2003;30(6 suppl 18):18-30.
6. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26(2 suppl 7):3-21.
7. Facorro G, Sarrasague MM, Torti et al. Oxidative study of patients with total body irradiation: effects of amifostine treatment. Bone Marrow Transplant. 2004;33:793-798.
8. McChesney SL, Gillette EL, Dewhirst MW, Withrow SJ. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1986;12:1957-1963.
9. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol. 2000;57:113-118.
10. Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 2004;70:261-264.
11. Boccia R, Anne PR, Bourhis J, et al. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys. 2004;60:302-309.
12. Koukourakis MI, Simopoulos C, Minopoulos G, et al. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res. 2003;9:3288-3293.
13. Bonner HS, Shaw IM. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol. 2002;42:166-174.
14. Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2002;29(6 suppl 19):57-60.
15. Kouloulias VE, Kouvaris JR, Pissakas G, et al. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. Int J Radiat Oncol Biol Phys. 2005;62:486-493.
16. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 2002;29(6 suppl 19):80-83.
17. Braaksma M, van Agthoven M, Nijdam W, Uyl-de Groot C, Levendag P. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer. 2005;41:2102-2111.
18. Werner-Wasik M, Langer C, Movsas B. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Semin Oncol. 2005;32(2 suppl 3):S105-S108.
19. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
20. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol. 2003;4:378-381.
21. Schuchter LM, Hensley ML, Meropol MJ, Winer EP, for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-2903.
22. Schuchter L, Merolpol N, Winder EP, Hensley ML, Somerfield MR. Amifostine and chemotherapy. ASCO responds. Lancet Oncol. 2003;4:593.
23. Systemic Treatment Disease Site Group. Vincent M, Bramwell V, Moran LA, Anderson D. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer [full report, online update]. Toronto, Canada: Cancer Care Ontario; 2003. Available at: http://www.guideline.gov/summary/summary.aspx? ss=15&doc_id=3703&nbr=2929. Accessed August 19, 2005.
24. Thongprasert S, Chewaskulyong B. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer. J Med Assoc Thai. 2004;87:1162-1167.
25. Ekborn A, Hansson J, Ehrsson H, et al. High-dose cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope. 2004;114:1660-1667.
26. Patlakas G, Bouros D, Tsantekidou-Pozova S, Koukourakis MI. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res. 2005;25:1427-1431.
27. Moore DH, Donnely J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase 11 study of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:4207-4213.
28. Scudder SA, Liu PY, Wilczynski SP, et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase 11 study of the Southwest Oncology Group. Gynecol Oncol. 2005;96:610-615.
29. Polyzos A, Tsavaris N, Kosmas C, et al. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. J Chemother. 2003;15:607-612.
30. Grosso D, Filicko J, Garcia-Manero G, et al. Cytoprotection in acute myelogenous leukemia (AML) therapy. Semin Oncol. 2004;31(6 suppl 18):67-73.
31. Giles FJ, Shi GG, Cortes JE, et al. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003;52:223-228.
32. Stokman MA, Wachters FM, Koopmans P, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis: a phase II study. Anticancer Res. 2004;24:3263-3267.
33. Tsavaris N, Kosmas C, Vadiaka M, et al. Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. J Pain Symptom Manage. 2003;26:849-854.
34. De Vos FY, Bos AM, Schaapveld M, et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol. 2005;97:60-67.
35. Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003;13:619-626.
36. Hilpert F, Stähle A, Tomé O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer. 2005;13:797-805.
37. Kanat O, Evrensel T, Baran I, et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol. 2003;20:237-245.
38. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol. 2003;179:385-389.
39. Suntharalingam M, Jaboin J, Taylor R, et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol. 2004;31(6 suppl 18):2-7.
40. Kutter J, Ozsahin M, Monnier P, Stupp R. Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol. 2005;262:1-7.
41. Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:72-77.
42. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004;58:1369-1377.
43. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999;45:1143-1149.
44. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol. 2005;23:2145-2154.
45. Antonadou D, Petridis A, Synodinou M, et al. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol. 2003;30(6 suppl 18):2-9.
46. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004;43:780-784.
47. Nguyen NP, Levinson B, Dutta S, et al. Amifostine and curative intent chemoradiation for compromised cancer patients. Anticancer Res. 2003;23:1649-1656.
48. Hwang WY, Koh LP, Ng HJ, et al. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34:51-56.
49. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res. 2004;10:461-467.
50. Benesch M, McDonald GB, Schubert M, Appelbaum FR, Deeg HJ. Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Bone Marrow Transplant. 2003;32:1071-1075.
51. Phillips GL, Abboud CN, Bernstein SH, et al. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation-a preliminary report. Semin Oncol. 2004;31(6 suppl 18):59-61.
52. Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2002;30:769-775.
53. Spencer A, Horvath N, Gibson J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 2005;35:971-977.
54. Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatr Blood Cancer. 2005;44:378-385.
55. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3:294-300.
56. Chen Q, Espey MQ, Krishna MC. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102:13604-13609.
57. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003;22:118-123.
58. Jatoi A, Williams B, Nichols F, et al. Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung Cancer. 2005;49:77-84.
59. Camphausen K, Citrin D, Krishna MC, Mitchell JB. Implications for tumor control during protection of normal tissues with antioxidants. J Clin Oncol. 2005;23:5455-5457.
60. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol. 2002;20:3302-3316.
61. Rock CL, Flatt SW, Thomson CA, et al. Effects of a high-fiber, low-fat diet intervention on serum concentrations of reproductive steroid hormones in women with a history of breast cancer. J Clin Oncol. 2004;22:2379-2387.
62. Ferreira PR, Fleck JF, Diehl A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck. 2004;26:313-321.
63. Sanchiz F, Milla A, Artola N, et al. Prevention of radioinduced cystitis by orgotein: a randomized study. Anticancer Res. 1996;16:2025-2028.
64. Chiao TB, Lee AJ. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann Pharmacother. 2005;39:516-522.
65. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001;19:3010-3017.
66. Seixas-Silva JA Jr, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg. 2005;131:304-307.
67. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53:43-46.
68. Sunila ES, Kuttan G. Protective effect of Thuja occidentalis against radiation-induced toxicity in mice. Integr Cancer Ther. 2005;4:322-328.
69. Jagetia GC, Venkatesh P, Baliga MS. Fruit extract of Aegle marmelos protects mice against radiation-induced lethality. Integr Cancer Ther. 2004;3:323-332.